Theratechnologies Inc. (TH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theratechnologies Inc. (TH) has a cash flow conversion efficiency ratio of -0.095x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.66 Million ≈ $1.92 Million USD) by net assets (CA$-27.92 Million ≈ $-20.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TH equity to assets ratio to measure how much of total assets are equity-financed.
Theratechnologies Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Theratechnologies Inc. to evaluate the quality of earnings relative to operating cash generation.
Theratechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theratechnologies Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Silver Exploration Corp.
V:SSV
|
-0.024x |
|
Inission AB (publ)
ST:INISS-B
|
0.058x |
|
Ekovest Bhd
KLSE:8877
|
0.159x |
|
Bonterra Energy Corp
TO:BNE
|
0.022x |
|
Casa de Bolsa Finamex S.A.B. de C.V
MX:FINAMEXO
|
0.039x |
|
GOLFZON Co. Ltd
KQ:215000
|
0.052x |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
0.041x |
|
Fong Chien Construction Co Ltd
TWO:5523
|
-0.115x |
Annual Cash Flow Conversion Efficiency for Theratechnologies Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of Theratechnologies Inc. from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see Theratechnologies Inc. (TH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | CA$-25.27 Million ≈ $-18.28 Million |
CA$2.38 Million ≈ $1.72 Million |
-0.094x | -134.60% |
| 2023-11-30 | CA$-20.87 Million ≈ $-15.10 Million |
CA$-5.68 Million ≈ $-4.11 Million |
0.272x | -58.20% |
| 2022-11-30 | CA$-22.57 Million ≈ $-16.33 Million |
CA$-14.69 Million ≈ $-10.63 Million |
0.651x | +179.85% |
| 2021-11-30 | CA$17.76 Million ≈ $12.85 Million |
CA$-14.48 Million ≈ $-10.47 Million |
-0.815x | +80.61% |
| 2020-11-30 | CA$3.22 Million ≈ $2.33 Million |
CA$-13.55 Million ≈ $-9.80 Million |
-4.204x | -2978.87% |
| 2019-11-30 | CA$24.83 Million ≈ $17.96 Million |
CA$-3.39 Million ≈ $-2.45 Million |
-0.137x | -1331.40% |
| 2018-11-30 | CA$35.05 Million ≈ $25.36 Million |
CA$-334.40K ≈ $-241.90K |
-0.010x | -116.76% |
| 2017-11-30 | CA$33.51 Million ≈ $24.24 Million |
CA$1.91 Million ≈ $1.38 Million |
0.057x | -43.11% |
| 2016-11-30 | CA$20.02 Million ≈ $14.48 Million |
CA$2.00 Million ≈ $1.45 Million |
0.100x | -71.72% |
| 2015-11-30 | CA$14.98 Million ≈ $10.83 Million |
CA$5.30 Million ≈ $3.83 Million |
0.354x | +134.63% |
| 2014-11-30 | CA$6.87 Million ≈ $4.97 Million |
CA$-7.02 Million ≈ $-5.08 Million |
-1.022x | -144.46% |
| 2013-11-30 | CA$17.45 Million ≈ $12.62 Million |
CA$-7.29 Million ≈ $-5.28 Million |
-0.418x | +39.39% |
| 2012-11-30 | CA$22.82 Million ≈ $16.51 Million |
CA$-15.74 Million ≈ $-11.39 Million |
-0.690x | +7.92% |
| 2011-11-30 | CA$35.20 Million ≈ $25.46 Million |
CA$-26.36 Million ≈ $-19.07 Million |
-0.749x | -1459.83% |
| 2010-11-30 | CA$51.65 Million ≈ $37.36 Million |
CA$2.84 Million ≈ $2.06 Million |
0.055x | -58.09% |
| 2009-11-30 | CA$40.70 Million ≈ $29.44 Million |
CA$5.35 Million ≈ $3.87 Million |
0.131x | +114.60% |
| 2008-11-30 | CA$37.80 Million ≈ $27.35 Million |
CA$-34.03 Million ≈ $-24.62 Million |
-0.900x | -83.28% |
| 2007-11-30 | CA$65.94 Million ≈ $47.70 Million |
CA$-32.39 Million ≈ $-23.43 Million |
-0.491x | +5.50% |
| 2006-11-30 | CA$38.96 Million ≈ $28.18 Million |
CA$-20.25 Million ≈ $-14.65 Million |
-0.520x | -487.37% |
| 2005-11-30 | CA$41.96 Million ≈ $30.35 Million |
CA$-3.71 Million ≈ $-2.69 Million |
-0.088x | +74.68% |
| 2004-11-30 | CA$53.02 Million ≈ $38.35 Million |
CA$-18.53 Million ≈ $-13.40 Million |
-0.349x | -6.85% |
| 2003-11-30 | CA$64.48 Million ≈ $46.65 Million |
CA$-21.09 Million ≈ $-15.26 Million |
-0.327x | -72.10% |
| 2002-11-30 | CA$79.51 Million ≈ $57.52 Million |
CA$-15.11 Million ≈ $-10.93 Million |
-0.190x | -58.13% |
| 2001-11-30 | CA$70.95 Million ≈ $51.32 Million |
CA$-8.53 Million ≈ $-6.17 Million |
-0.120x | -1.33% |
| 2000-11-30 | CA$38.53 Million ≈ $27.87 Million |
CA$-4.57 Million ≈ $-3.31 Million |
-0.119x | +40.93% |
| 1999-11-30 | CA$16.91 Million ≈ $12.23 Million |
CA$-3.40 Million ≈ $-2.46 Million |
-0.201x | +38.66% |
| 1998-11-30 | CA$10.94 Million ≈ $7.91 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.327x | +35.81% |
| 1997-11-30 | CA$7.03 Million ≈ $5.08 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.510x | -102.72% |
| 1996-11-30 | CA$11.80 Million ≈ $8.54 Million |
CA$-2.97 Million ≈ $-2.15 Million |
-0.252x | -- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more